• 1. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 2. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 3. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 4. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 5. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig

6-Methoxy-quinazolin-4-ylamine: A Promising Compound in Pharmaceutical Research

6-Methoxy-quinazolin-4-ylamine (CAS No. 885277-51-0) is a versatile compound that has garnered significant attention in the field of pharmaceutical research due to its potential therapeutic applications. This compound belongs to the class of quinazoline derivatives, which are known for their diverse biological activities, including anti-cancer, anti-inflammatory, and anti-viral properties. In this article, we will delve into the chemical structure, synthesis methods, biological activities, and recent research advancements of 6-Methoxy-quinazolin-4-ylamine.

Chemical Structure and Synthesis

6-Methoxy-quinazolin-4-ylamine is characterized by its unique chemical structure, which includes a quinazoline ring system with a methoxy group at the 6-position and an amino group at the 4-position. The methoxy group contributes to the compound's lipophilicity and stability, while the amino group provides a reactive site for further functionalization. The synthesis of 6-Methoxy-quinazolin-4-ylamine typically involves multi-step processes, including the formation of the quinazoline ring and subsequent functional group modifications.

One common synthetic route involves the condensation of anthranilic acid with an appropriate amine to form the quinazoline core, followed by methylation at the 6-position and reduction of the nitro group to an amino group. Recent advancements in synthetic chemistry have led to more efficient and environmentally friendly methods, such as microwave-assisted synthesis and catalytic processes, which have improved the yield and purity of 6-Methoxy-quinazolin-4-ylamine.

Biological Activities

The biological activities of 6-Methoxy-quinazolin-4-ylamine have been extensively studied in various in vitro and in vivo models. One of the most notable applications is its potential as an anti-cancer agent. Research has shown that 6-Methoxy-quinazolin-4-ylamine exhibits potent cytotoxic effects against several cancer cell lines, including breast cancer, lung cancer, and colon cancer. The mechanism of action is believed to involve the inhibition of key signaling pathways involved in cell proliferation and survival.

In addition to its anti-cancer properties, 6-Methoxy-quinazolin-4-ylamine has also demonstrated anti-inflammatory effects. Studies have shown that it can inhibit the production of pro-inflammatory cytokines such as TNF-alpha and IL-6, making it a potential candidate for treating inflammatory diseases. Furthermore, preliminary research suggests that 6-Methoxy-quinazolin-4-ylamine may have anti-viral properties, particularly against RNA viruses like influenza.

Clinical Trials and Future Prospects

The promising preclinical results of 6-Methoxy-quinazolin-4-ylamine have led to increased interest in its clinical development. Several Phase I and Phase II clinical trials are currently underway to evaluate its safety and efficacy in treating various diseases. Early results from these trials have been encouraging, with no major adverse effects reported at therapeutic doses.

In parallel with clinical trials, ongoing research is focused on optimizing the pharmacokinetic properties of 6-Methoxy-quinazolin-4-ylamine. This includes improving its solubility, bioavailability, and metabolic stability through structural modifications or formulation strategies. Additionally, efforts are being made to identify biomarkers that can predict patient response to treatment, thereby enhancing personalized medicine approaches.

Conclusion

6-Methoxy-quinazolin-4-ylamine (CAS No. 885277-51-0) is a promising compound with a wide range of potential therapeutic applications. Its unique chemical structure and diverse biological activities make it an attractive target for further research and development. As clinical trials progress and more data become available, it is likely that this compound will play a significant role in advancing our understanding and treatment of various diseases.

• 21575-13-3(4-Amino-6,7-dimethoxyquinazoline)
• 21560-97-4(4-Amino-7-methoxyquinazoline)
• 27018-21-9(5-Methoxy-quinazoline-2,4-diamine)
• 63590-63-6(2-Chloro-6-methoxyquinazolin-4-amine)
• 137105-47-6(5-METHOXY-QUINAZOLINE-2,4-DIAMINE)
• 60547-96-8(6,7-Dimethoxy-2,4-quinazolinediamine)
• 320366-15-2(7-Quinazolinol, 4-amino-)
• 38711-03-4(2,4-Quinazolinediamine, 6-phenoxy-)
• 885277-54-3(5-Methoxy-quinazolin-4-ylamine)
• 320365-90-0(7-Quinazolinol, 4-amino-6-methoxy-)